ALC · NYSE
Alcon Inc.
$70.18 -0.44 (-0.62%)
Company overview
Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. Its Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses, and other implantables, as well as consumables including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Cataract products include the Centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements, along with custom pak surgical procedure packs.
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Exchange
- NYSE
- Market cap
- $33.9B
- Employees
- 25,628
- Headquarters
- Geneva, GE
- Website
- alcon.com
- CEO
- David J. Endicott
- Listed
- April 9, 2019
- P/E
- 42.28
- Dividend yield
- 0.55%
Company financials
- Revenue
- $10.6B
- Gross profit
- $5.8B
- Operating income
- $1.3B
- EBITDA
- $2.1B
- Net income
- $815M
- EPS
- $1.66
- Total assets
- $31.8B
- Total debt
- $5.3B
- Gross margin
- 54.95%
- Net margin
- 7.71%
- Earnings yield
- 2.37%
No product segmentation.
Showing FY 2025
ALC
1D
NYSE
O68.02H70.68L67.96C70.63+3.20 (+4.75%)Vol2.21M